Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, has opened its new office location at the Singapore Science Park. The new base strengthens its Singapore presence and complements its offices in the United States at Texas Medical Centre and South San Francisco.
“This new facility is a significant milestone and will allow us to significantly strengthen the team and add capabilities,” said Dr. Piers Ingram, Chief Executive Officer and co-founder of Hummingbird Bioscience. “We are excited to welcome more members to the growing Hummingbird family, to join us on our mission to discover and develop important new medicines.”
The 40,000 sq. ft. space includes state-of-the-art laboratories integrated alongside office space, which will bolster antibody discovery, engineering, and pharmacology, as well as cell line and process development. The enhanced facilities will allow Hummingbird Bioscience to accelerate development of its pipeline of precision therapies.
“We are continuously searching for passionate individuals who are motivated to solve complex scientific problems with creative solutions,” said Dr. Jerome Boyd-Kirkup, Chief Scientific Officer and co-founder of Hummingbird Bioscience.
Hummingbird Bioscience is located at The Galen, 61 Science Park Road, Singapore.